Upjohn’s Shuck and Jive Routine

Every once in a while an instance of product dumping comes along that is so blatant, you have to rub your eyes and look again. Consider the case of Panalba.

Panalba was an antibiotic made by the large, U.S.-based Upjohn Company. It was launched in 1957 and promoted heavily. By 1968, Panalba sales totaled $18 million, or 12 percent of Upjohn’s domestic gross income. Yet in that same year and the two that followed, strong scientific evidence of Panalba’s harm appeared:

  • In 1968, 30 experts from the National Academy of Sciences issued a unanimous report on Panalba and 49 other antibiotics of a similar nature. These drugs are harmful, the scientists said; they should be removed from the market.

  • On May 27, 1969, FDA Commissioner Herbert Ley Jr., himself a specialist in antibiotics, testified before a Senate committee about the effects of novobiocin, one of the two ingredients of Panalba. Roughly one out of every five patients who receives it, Ley said, has an allergic reaction.

  • Twelve patients receiving Panalba died as a result of its side effects (mostly from blood disorders).

  • FDA inspector Roy Sanberg, searching Upjohn files, discovered several ten-year-old company-sponsored studies showing that tetracycline, the other of Panalba’s two ingredients, was more effective than Panalba, when used alone.

    After much bureaucratic wrangling and resistance by Upjohn, the FDA finally forced Panalba off the market in 1970.

    If you think all this evidence against Panalba would make its manufacturer think twice before selling it elsewhere, think again. Under FDA regulations, antibiotics are not legally classified as “drugs.” Were Panalba considered a drug, it would undoubtedly have lost its FDA approval and, thus, been illegal for export. But because of this classic loophole in the law, it is now perfectly legal for Upjohn to export Panalba. (Actually, its two ingredients are exported separately and combined and packaged in Upjohn’s foreign plants.) Today, after being the target of one of the strongest cases against a drug in regulatory history, Panalba is sold in 33 countries under another name — Albamycin-T.


    The more we thought about how MoJo's journalism can have the most impact heading into the 2020 election, the more we realized that so many of today's stories come down to corruption: democracy and the rule of law being undermined by the wealthy and powerful for their own gain.

    So we're launching a new Mother Jones Corruption Project to do deep, time-intensive reporting on systemic corruption. We aim to hire, build a team, and give them the time and space needed to understand how we got here and how we might get out. We'll publish what we find as a major series in the summer of 2020, including a special issue of our magazine, a dedicated online portal, and video and podcast series so it doesn't get lost in the daily deluge of breaking news.

    It's unlike anything we've done before and we've got seed funding to get started, but we're asking readers to help crowdfund this new beat with an additional $500,000 so we can go even bigger. You can read why we're taking this approach and what we want to accomplish in "Corruption Isn't Just Another Scandal. It's the Rot Beneath All of Them," and if you like how it sounds, please help fund it with a tax-deductible donation today.

    We Recommend


    Sign up for our newsletters

    Subscribe and we'll send Mother Jones straight to your inbox.

    Get our award-winning magazine

    Save big on a full year of investigations, ideas, and insights.


    Support our journalism

    Help Mother Jones' reporters dig deep with a tax-deductible donation.